See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
yue chen
the Affiliated Hospital of Southwest Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Soft-tissue metastasis (STM) is a relatively rare, but not exceptional, manifestation of lung cancer. Since the lesions of STM are usually asymptomatic, they are easy to miss during clinical evaluation. The aim of the study was to explore the incidence and characteristics of STM in lung cancer using fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT), and evaluate its effect on tumor staging and treatment. Methods We analyzed 4543 patients with lung cancer who underwent 18 F-FDG PET/CT in our hospital between January 2013 and September 2018. 85 were diagnosed with STM and included in the study group. Imaging characteristics, clinical symptoms, and survival time (from confirmed STM to death) were recorded for all study subjects. Results A total of 219 lesions were identified by 18 F-FDG PET/CT: 215 were detected by PET (maximum standardized uptake value = 6.12); 139 were detected by CT. Muscle STM were primarily found in the hip, upper limb muscle; whereas subcutaneous STM were mainly distributed in the chest and abdomen, back. In 68 patients (80%), STM were found incidentally during routine 18 F-FDG PET/CT staging. The lesions were symptomatic in 17 cases (20%); in 10 patients (11.8%) STM was the first manifestation. Other site metastases were detected in 79 patients (92.9%). Isolated STM were found in 6 patients (7.1%), whose tumor staging and treatment were affected by PET/CT findings. At the end of the follow-up period, 69 patients were dead (median survival time= 5.0 months) and 5 were lost to follow-up. Conclusions STM may be a sign of advanced stage and poor prognosis in lung cancer. 18 F-FDG PET/CT is highly valuable in the detection of STM, and can impact tumor staging and management of lung malignancies.
Keywords
18F-FDG, lung cancer, soft-tissue, metastasis, PET/CT
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 1
Posted 10 Mar, 2020
No community comments so far
Editorial decision: Major revision
On 16 Mar, 2020
Review #1 received
Received 16 Mar, 2020
Review #2 received
Received 13 Mar, 2020
Reviewer #2 agreed
On 07 Mar, 2020
Reviewers invited
Invitations sent on 06 Mar, 2020
Reviewer #1 agreed
On 06 Mar, 2020
Editor assigned
On 04 Mar, 2020
First submitted
On 03 Mar, 2020
Submission checks complete
On 03 Mar, 2020
Editor invited
On 03 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
yue chen
the Affiliated Hospital of Southwest Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 1
Posted 10 Mar, 2020
No community comments so far
Editorial decision: Major revision
On 16 Mar, 2020
Review #1 received
Received 16 Mar, 2020
Review #2 received
Received 13 Mar, 2020
Reviewer #2 agreed
On 07 Mar, 2020
Reviewers invited
Invitations sent on 06 Mar, 2020
Reviewer #1 agreed
On 06 Mar, 2020
Editor assigned
On 04 Mar, 2020
First submitted
On 03 Mar, 2020
Submission checks complete
On 03 Mar, 2020
Editor invited
On 03 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background Soft-tissue metastasis (STM) is a relatively rare, but not exceptional, manifestation of lung cancer. Since the lesions of STM are usually asymptomatic, they are easy to miss during clinical evaluation. The aim of the study was to explore the incidence and characteristics of STM in lung cancer using fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT), and evaluate its effect on tumor staging and treatment. Methods We analyzed 4543 patients with lung cancer who underwent 18 F-FDG PET/CT in our hospital between January 2013 and September 2018. 85 were diagnosed with STM and included in the study group. Imaging characteristics, clinical symptoms, and survival time (from confirmed STM to death) were recorded for all study subjects. Results A total of 219 lesions were identified by 18 F-FDG PET/CT: 215 were detected by PET (maximum standardized uptake value = 6.12); 139 were detected by CT. Muscle STM were primarily found in the hip, upper limb muscle; whereas subcutaneous STM were mainly distributed in the chest and abdomen, back. In 68 patients (80%), STM were found incidentally during routine 18 F-FDG PET/CT staging. The lesions were symptomatic in 17 cases (20%); in 10 patients (11.8%) STM was the first manifestation. Other site metastases were detected in 79 patients (92.9%). Isolated STM were found in 6 patients (7.1%), whose tumor staging and treatment were affected by PET/CT findings. At the end of the follow-up period, 69 patients were dead (median survival time= 5.0 months) and 5 were lost to follow-up. Conclusions STM may be a sign of advanced stage and poor prognosis in lung cancer. 18 F-FDG PET/CT is highly valuable in the detection of STM, and can impact tumor staging and management of lung malignancies.
Figure 1
Figure 2
Figure 3
Loading...